ThermoGenesis Holdings (NASDAQ:THMO) reported quarterly losses of $(0.10) per share. This is a 33.33 percent increase over losses of $(0.15) per share from the same period last year.
HC Wainwright & Co. Initiates Coverage On Clearside Biomedical with Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Yi Chen initiates coverage on Clearside Biomedical (NASDAQ:CLSD) with a Buy rating and announces Price Target of $10.